Search - tctmd.com

Displaying 1 - 20 of 36

Sort: Relevancy | Date

News Daily News

Top Endovascular News of 2024

L.A. McKeown

December 28, 2024

News Daily News

Top Coronary Artery Disease News in 2024

Michael O'Riordan

December 26, 2024

Presentation TCT 2024

Sirolimus- vs. Paclitaxel-Coated Balloons for the Treatment?of Coronary Artery Disease

Presenter: Pier Pasquale Leone

October 30, 2024

Presentation TCT 2024

Paclitaxel, Sirolimus, Biolimus: The Art of DCBs Selection

Presenter: Joanna Wykrzykowska

October 30, 2024

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

L.A. McKeown

October 29, 2024

Presentation TCT 2024

TCT 500: Long-term Outcomes and Predictor of Target Lesion Revascularization the Patients After Treated With Paclitaxel Coated Balloon for Drug-Eluted Stent Restenosis

Presenter: Ikuta Akihiro

October 29, 2024

Presentation TCT 2024

TCT 501: Paclitaxel-Coated Balloon vs. Uncoated Balloon Angioplasty for Coronary In-Stent Restenosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Presenter: Dealla Samadi

October 29, 2024

Presentation TCT 2024

Head-to-Head Comparison of Sirolimus- Versus Paclitaxel-Coated Balloon Angioplasty in the Femoropopliteal Artery: The SIRONA Randomized Controlled Trial

Presenter: Ulf Teichgräber

October 29, 2024

Presentation TCT 2024

TCT 495: The Impact of Cutting Balloon Pre-Dilation on the Outcomes of Paclitaxel Drug-Coated Balloon Treatment for Coronary In-Stent Restenosis

Presenter: Yuanji Ma

October 29, 2024

Presentation TCT 2024

TCT 497: Sex-Specific Clinical Outcomes After Treatment of In-Stent Restenosis With the AGENT Paclitaxel-Coated Balloon: A Subgroup Analysis of the AGENT IDE Randomized Trial

Presenter: Jennifer Tremmel

October 29, 2024

Presentation TCT 2024

TCT 700: Drug-Loss at Arterial Bends Can Dominate Off-Target Drug Delivery by Paclitaxel-Coated Balloons

Presenter: Linnea Tscheuschner

October 29, 2024

Presentation TCT 2024

TCT 455: Quantitative Coronary Dissection Volume After Sirolimus or Paclitaxel Coated Balloon and Lumen Changes at 6 Months: Serial OCT Sub-study of TRANSFORM-I Trial

Presenter: Akihiro Tobe

October 29, 2024

Presentation TCT 2024

TCT 451: Plaque Changes and Vessel Remodeling After Balloon Angioplasty for De Novo Coronary Lesions Using Paclitaxel-Coated Balloons: A Serial IB-IVUS Study

Presenter: Shelby Kerr

October 29, 2024

News Conference News TCT 2024

DCB Outdo Noncompliant Balloons in Simple Bifurcation Side Branches: DCB-BIF

Caitlin E. Cox

October 28, 2024

Presentation TCT 2024

TCT 41: Paclitaxel-Coated Versus Sirolimus-Coated Balloon Angioplasty for Coronary Artery Disease: A Systematic Review and Meta-Analysis

Presenter: Doosup Shin

October 28, 2024

Presentation TCT 2024

TCT 40: Sirolimus- vs. Paclitaxel-Coated Balloons for Treatment of Coronary Artery Disease

Presenter: Pier Pasquale Leone

October 28, 2024

Presentation TCT 2024

TCT 491: AGENT Paclitaxel-Coated Balloon for the Treatment of In-Stent Restenosis in Small Vessel Coronary Lesions: A Subgroup Analysis of the AGENT IDE Randomized Trial

Presenter: Suhail Dohad

October 28, 2024

Presentation TCT 2024

TCT 436: Paclitaxel-Coated Balloon With Urea or Iopromide as the Excepient for Treatment of Coronary Artery Disease: A Propensity-Score Adjusted Comparison

Presenter: Mauro Gitto

October 28, 2024

Presentation TCT 2024

TCT 492: One-Year Clinical Outcomes After PCI With AGENT Paclitaxel-Coated Balloon Among Underrepresented Racial and Ethnic Subgroups With In-Stent Restenosis: Analysis of the AGENT IDE Trial

Presenter: NULL

October 28, 2024

Presentation TCT 2024

Drug Delivery Technologies for the SFA: Where are We Now After the Paclitaxel Scare?

Presenter: Sahil Parikh

October 28, 2024

Advertisement

Top Endovascular News of 2024

Top Coronary Artery Disease News in 2024

Sirolimus- vs. Paclitaxel-Coated Balloons for the Treatment?of Coronary Artery Disease

Paclitaxel, Sirolimus, Biolimus: The Art of DCBs Selection

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

TCT 500: Long-term Outcomes and Predictor of Target Lesion Revascularization the Patients After Treated With Paclitaxel Coated Balloon for Drug-Eluted Stent Restenosis

TCT 501: Paclitaxel-Coated Balloon vs. Uncoated Balloon Angioplasty for Coronary In-Stent Restenosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Head-to-Head Comparison of Sirolimus- Versus Paclitaxel-Coated Balloon Angioplasty in the Femoropopliteal Artery: The SIRONA Randomized Controlled Trial

TCT 495: The Impact of Cutting Balloon Pre-Dilation on the Outcomes of Paclitaxel Drug-Coated Balloon Treatment for Coronary In-Stent Restenosis

TCT 497: Sex-Specific Clinical Outcomes After Treatment of In-Stent Restenosis With the AGENT Paclitaxel-Coated Balloon: A Subgroup Analysis of the AGENT IDE Randomized Trial

TCT 700: Drug-Loss at Arterial Bends Can Dominate Off-Target Drug Delivery by Paclitaxel-Coated Balloons

TCT 455: Quantitative Coronary Dissection Volume After Sirolimus or Paclitaxel Coated Balloon and Lumen Changes at 6 Months: Serial OCT Sub-study of TRANSFORM-I Trial

TCT 451: Plaque Changes and Vessel Remodeling After Balloon Angioplasty for De Novo Coronary Lesions Using Paclitaxel-Coated Balloons: A Serial IB-IVUS Study

DCB Outdo Noncompliant Balloons in Simple Bifurcation Side Branches: DCB-BIF

TCT 41: Paclitaxel-Coated Versus Sirolimus-Coated Balloon Angioplasty for Coronary Artery Disease: A Systematic Review and Meta-Analysis

TCT 40: Sirolimus- vs. Paclitaxel-Coated Balloons for Treatment of Coronary Artery Disease

TCT 491: AGENT Paclitaxel-Coated Balloon for the Treatment of In-Stent Restenosis in Small Vessel Coronary Lesions: A Subgroup Analysis of the AGENT IDE Randomized Trial

TCT 436: Paclitaxel-Coated Balloon With Urea or Iopromide as the Excepient for Treatment of Coronary Artery Disease: A Propensity-Score Adjusted Comparison

TCT 492: One-Year Clinical Outcomes After PCI With AGENT Paclitaxel-Coated Balloon Among Underrepresented Racial and Ethnic Subgroups With In-Stent Restenosis: Analysis of the AGENT IDE Trial

Drug Delivery Technologies for the SFA: Where are We Now After the Paclitaxel Scare?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content